From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
COVARIATES
OR (95% CI)
P
GH at baseline (μg/L)
1.015 (0.983-1.043)
1.047
IGF-I SDS at baseline
1.003 (0.999-1.007)
0.097
Δ IGF IaSDS
1.446 (1.153-1.814)
0.001
Detectable adenoma at baseline b
13.757 (2.547-74.307)
0.002